Press Releases April 27, 2026 07:00 AM

Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

Harrow Announces Q1 2026 Financial Results Release and Conference Call Scheduled for May

By Nina Shah HROW

Harrow, a Nasdaq-listed ophthalmic disease management company, will release its financial results for Q1 2026 after market close on May 11, followed by a conference call on May 12 to discuss the results and provide a business update.

Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
HROW

Key Points

  • Harrow is reporting financial results for Q1 2026 ending March 31, 2026.
  • The company will host a conference call and webcast on May 12, 2026, to discuss these results.
  • Harrow specializes in ophthalmic disease management, targeting various eye conditions affecting front and back of the eye.

NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the first quarter ended March 31, 2026, on Monday, May 11, 2026, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, May 12, 2026, to discuss the results and provide a business update.

Conference Call Information
Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.

To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Contact:
Mike Biega
VP of Investor Relations & Communications
[email protected]
617-913-8890


Risks

  • Financial results could underperform market expectations potentially impacting stock price.
  • Ophthalmic pharmaceutical market is competitive with uncertainties in regulatory approvals and reimbursement.
  • Market and economic conditions affecting healthcare spending may impact company performance.

More from Press Releases

Redwing Dewatering Program On Schedule May 19, 2026 Brady Corporation declares regular dividend to shareholders May 19, 2026 Hudbay Announces Election of Directors at 2026 Annual and Special Meeting of Shareholders May 19, 2026 Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease May 19, 2026 Inno Holdings Inc. Announces $60.0 Million “At-the-Market” Equity Offering Program May 19, 2026